on July 14, 2003
Circulation. 2003
Published online before print July 14, 2003, doi: 10.1161/01.CIR.0000080895.05158.8B
Published online before print July 14, 2003, doi: 10.1161/01.CIR.0000080895.05158.8B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 19, 2003
From the Departments of Cell Biology, Cardiovascular Medicine, and the Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio. * To whom correspondence should be addressed. E-mail: hazens{at}ccf.org.
Background--The pleiotropic actions of hydroxymethylglutaryl CoA reductase inhibitors (statins) include antiinflammatory and antioxidant actions. We recently reported that statins induce reductions in plasma protein levels of nitrotyrosine (NO2Tyr), a modification generated by nitric oxide-derived oxidants. Whether alternative oxidative pathways are suppressed in vivo after statin administration has not yet been reported. Methods and Results--As an extension of our prior study, hypercholesterolemic subjects with no known coronary artery disease were evaluated at baseline and after 12 weeks of atorvastatin therapy (10 mg/d). Plasma levels of protein-bound chlorotyrosine, NO2Tyr, dityrosine, and orthotyrosine, specific molecular fingerprints for distinct oxidative pathways upregulated in atheroma, were determined by mass spectrometry. In parallel, alterations in lipoproteins and C-reactive protein were determined. Statin therapy caused significant reductions in chlorotyrosine, NO2Tyr, and dityrosine (30%, 25%, and 32%, respectively; P<0.02 each) that were similar in magnitude to reductions in total cholesterol and apolipoprotein B-100 (25% and 29%, P<0.001 each). Nonsignificant decreases in orthotyrosine and C-reactive protein levels were observed (9% and 11%, respectively; P>0.10 each). Statin-induced reductions in oxidation markers were independent of decreases in lipids and lipoproteins. Conclusions--Statins promote potent systemic antioxidant effects through suppression of distinct oxidation pathways. The major pathways inhibited include formation of myeloperoxidase-derived and nitric oxide-derived oxidants, species implicated in atherogenesis. The present results suggest potential mechanisms that may contribute to the beneficial actions of statins. They also have important implications for monitoring the antiinflammatory and antioxidant actions of these agents.
Revised on May 6, 2003
Accepted on May 7, 2003
Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways
Mehdi H. Shishehbor DO,
Key words: statins • antioxidants • hypercholesterolemia • atherosclerosis • inflammation
This article has been cited by other articles:
 |
|
 |
|
  L. Zhang, Y. Liu, X. T. Lu, Y. L. Wu, C. Zhang, X. P. Ji, R. Wang, C. X. Liu, J. B. Feng, H. Jiang, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2004 - H2014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Anselmi, G. Possati, and M. Gaudino Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann. Thorac. Surg., July 1, 2009; 88(1): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Bruner-Tran, K. G. Osteen, and A. J. Duleba Simvastatin Protects against the Development of Endometriosis in a Nude Mouse Model J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2489 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thomson, M. P. Frenneaux, and J. C. Kaski Antioxidant treatment for heart failure: friend or foe? QJM, May 1, 2009; 102(5): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nicholls and S. L. Hazen Myeloperoxidase, modified lipoproteins, and atherogenesis J. Lipid Res., April 1, 2009; 50(Supplement): S346 - S351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kaireviciute, A. Aidietis, and G. Y.H. Lip Atrial fibrillation following cardiac surgery: clinical features and preventative strategies Eur. Heart J., February 2, 2009; 30(4): 410 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. SHISHEHBOR and S. L. HAZEN JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 37 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Spatz, M. E. Canavan, and M. M. Desai From Here to JUPITER: Identifying New Patients for Statin Therapy Using Data From the 1999-2004 National Health and Nutrition Examination Survey Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kourliouros, A. De Souza, N. Roberts, A. Marciniak, A. Tsiouris, O. Valencia, J. Camm, and M. Jahangiri Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery Ann. Thorac. Surg., May 1, 2008; 85(5): 1515 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Guasti, F. Marino, M. Cosentino, R. C. Maio, E. Rasini, M. Ferrari, L. Castiglioni, C. Klersy, G. Gaudio, A. M. Grandi, et al. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up Eur. Heart J., May 1, 2008; 29(9): 1118 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ky, A. Burke, S. Tsimikas, M. L. Wolfe, M. G. Tadesse, P. O. Szapary, J. L. Witztum, G. A. FitzGerald, and D. J. Rader The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Walter, R. F. Jacob, R. E. Bjork, B. Jeffers, J. Buch, Y. Mizuno, R. P. Mason, and on behalf of the PREVENT Investigators Circulating Lipid Hydroperoxides Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease: The PREVENT Study J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1196 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, D. Sosnovik, J. W. Chen, P. Panizzi, J.-L. Figueiredo, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury Circulation, March 4, 2008; 117(9): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Cangemi, L. Loffredo, R. Carnevale, L. Perri, M. P. Patrizi, V. Sanguigni, P. Pignatelli, and F. Violi Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E Eur. Heart J., January 1, 2008; 29(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Keddissi, W. G. Younis, E. A. Chbeir, N. N. Daher, T. A. Dernaika, and G. T. Kinasewitz The Use of Statins and Lung Function in Current and Former Smokers Chest, December 1, 2007; 132(6): 1764 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Radaelli, C. Loardi, M. Cazzaniga, G. Balestri, C. DeCarlini, M. G. Cerrito, E. N. Cusa, L. Guerra, S. Garducci, D. Santo, et al. Inflammatory Activation During Coronary Artery Surgery and Its Dose-Dependent Modulation by Statin/ACE-Inhibitor Combination Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2750 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Peluffo and R. Radi Biochemistry of protein tyrosine nitration in cardiovascular pathology Cardiovasc Res, July 15, 2007; 75(2): 291 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.S. Kostapanos, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf Do statins have an antiarrhythmic activity? Cardiovasc Res, July 1, 2007; 75(1): 10 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugita, H. Sugita, and M. Kaneki Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Van Gelder Rhythm control for atrial fibrillation: Non-channel antiarrhythmic drugs are en vogue Cardiovasc Res, April 1, 2007; 74(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure Cardiovasc Res, April 1, 2007; 74(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Van Antwerpen, K. Z. Boudjeltia, M. Vaes, S. Babar, P. Madhoun, N. Moguilevsky, M. Vanhaeverbeek, J. Neve, and J. Ducobu The pleiotropic effect of statins in haemodialysis patients is not the consequence of an inhibition of LDL oxidation by myeloperoxidase Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2672 - 2674. [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Collard, S. C. Body, S. K. Shernan, S. Wang, D. T. Mangano, and Multicenter Study of Perioperative Ischemia (MCSPI Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 392 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Hothersall, C McSharry, and N C Thomson Potential therapeutic role for statins in respiratory disease. Thorax, August 1, 2006; 61(8): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. K. Klein, R. Klein, K. E. Lee, and L. M. Grady Statin Use and Incident Nuclear Cataract JAMA, June 21, 2006; 295(23): 2752 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nawrot, A. Nemmar, and B. Nemery Update in environmental and occupational medicine 2005. Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 948 - 952. [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Mason, M. F. Walter, C. A. Day, and R. F. Jacob Active Metabolite of Atorvastatin Inhibits Membrane Cholesterol Domain Formation by an Antioxidant Mechanism J. Biol. Chem., April 7, 2006; 281(14): 9337 - 9345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Dalle-Donne, R. Rossi, R. Colombo, D. Giustarini, and A. Milzani Biomarkers of Oxidative Damage in Human Disease Clin. Chem., April 1, 2006; 52(4): 601 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, E. Rodriguez-Ayala, Z. A. Massy, A. R. Qureshi, P. Barany, B. Fellstrom, O. Heimburger, B. Lindholm, and A. Alvestrand Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 281 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Erdos, J. A. Snipes, C. D. Tulbert, P. Katakam, A. W. Miller, and D. W. Busija Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1264 - H1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Wazni, D O Martin, N F Marrouche, M Shaaraoui, M K Chung, S Almahameed, R A Schweikert, W I Saliba, and A Natale C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion Heart, October 1, 2005; 91(10): 1303 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pleiner, G. Schaller, F. Mittermayer, S. Zorn, C. Marsik, S. Polterauer, S. Kapiotis, and M. Wolzt Simvastatin Prevents Vascular Hyporeactivity During Inflammation Circulation, November 23, 2004; 110(21): 3349 - 3354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Walter, R. F. Jacob, B. Jeffers, M. M. Ghadanfar, G. M. Preston, J. Buch, and R. P. Mason Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Spyridopoulos, J. Haendeler, C. Urbich, T. H. Brummendorf, H. Oh, M. D. Schneider, A. M. Zeiher, and S. Dimmeler Statins Enhance Migratory Capacity by Upregulation of the Telomere Repeat-Binding Factor TRF2 in Endothelial Progenitor Cells Circulation, November 9, 2004; 110(19): 3136 - 3142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, G. Schram, J. Lavoie, and S. Nattel Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs Circulation, October 19, 2004; 110(16): 2313 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Pan, T. Pintar, J. Anton, V.-V. Lee, W. K. Vaughn, and C. D. Collard Statins Are Associated With a Reduced Incidence of Perioperative Mortality After Coronary Artery Bypass Graft Surgery Circulation, September 14, 2004; 110(11_suppl_1): II-45 - II-49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vishnevetsky, V. A Kiyanista, and P. J Gandhi CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease Ann. Pharmacother., September 1, 2004; 38(9): 1500 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Mangoni Diastolic and Pulse Pressure: The Old and the New? Hypertension, March 1, 2004; 43(3): 531 - 532. [Full Text] [PDF]
|
|
|
|
 |
|
 E. POLIAKOV, M.-L. BRENNAN, J. MACPHERSON, R. ZHANG, W. SHA, L. NARINE, R. G. SALOMON, and S. L. HAZEN Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo FASEB J, December 1, 2003; 17(15): 2209 - 2220. [Abstract] [Full Text] [PDF]
|
|